Since then, rapid advancement has been made in targeted therapy for this pathway, leading to the approval of osimertinib, a third-generation EGFR inhibitor, in 2018 for first-line management of advanced NSCLC [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.